Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The FDA's 2015 and subsequent guidance documents have questioned whether AOD-9604 qualifies as a bulk substance under 503A compounding rules, because it is not a component of an FDA-approved drug with the same active ingredient
Indications: Depression typically for patients who do not respond to SSRIs, NDRIs and other 2nd or 3rd generation antidepressants Neuropathic (Chronic) pain Neuropathic pain does not typically respond to classic analgesics, or opioids
J Clin Invest 127(5):16311645 Olalla L, Gutirrez A, Campos JA et al (2002) Nuclear localization of L-type glutaminase in mammalian brain
Biomimetic NanoCancer Stem Cell Scavenger for Inhibition of Breast Cancer Recurrence and Metastasis after FLASHRadiotherapy
PMC 178850
US$ 28.52
US$ 27.20
US$ 26.81
US$ 29.14
US$ 24.76
US$ 25.13
